Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.61 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996059 | 0.84 | CCR3 (0.49) | CD274CCR3MKNK1MKNK2DPP4 | |
| SCHEMBL7033543 | 0.83 | CCR3 (0.48) | CD274CCR3MKNK1MKNK2DPP4 | |
| SCHEMBL7027153 | 0.83 | CCR3 (0.48) | CD274CCR3MKNK1MKNK2DPP4 | |
| SCHEMBL6995882 | 0.83 | DRD3 (0.52) | CD274CCR3MKNK1MKNK2DPP4 | |
| SCHEMBL6997557 | 0.83 | CCR3 (0.48) | CD274CCR3MKNK1MKNK2DPP4 | |
| SCHEMBL6995153 | 0.82 | CCR3 (0.52) | CCR3EPHX2CHRM4 | |
| SCHEMBL7036069 | 0.82 | KCNH2 (0.52) | CD274MKNK1MKNK2DRD3ALDH1A1 | |
| SCHEMBL5318392 | 0.82 | CD274 (0.58) | CD274CCR3MKNK1MKNK2DPP4 | |
| SCHEMBL5317499 | 0.80 | CD274 (0.56) | CD274CCR3MKNK1MKNK2DPP4 | |
| SCHEMBL5316471 | 0.80 | CD274 (0.56) | CD274CCR3MKNK1MKNK2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | CD274 3866/4885CCR3 4291/4885MKNK1 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.